Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Levesque

Showing results (331-340 of 344) with videos related to

Pageof 35
Sort By:
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Plos One|January 14, 2021
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activityJason Ptacek, Rachael E Hawtin, Dongmei Sun, et al.
Journal of Medicinal Chemistry|February 21, 2019
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical TrialsJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Frontiers in Immunology|March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβYunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Journal of Medicinal Chemistry|February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Journal of Medicinal Chemistry|February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 35

Showing results (331-340 of 344) with videos related to

Sort By:
Pageof 35
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Plos One|January 14, 2021
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activityJason Ptacek, Rachael E Hawtin, Dongmei Sun, et al.
Journal of Medicinal Chemistry|February 21, 2019
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical TrialsJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Frontiers in Immunology|March 8, 2024
IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβYunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, et al.
Journal of Medicinal Chemistry|February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Journal of Medicinal Chemistry|February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infectionPaul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 35